-
公开(公告)号：US20120148613A1
公开(公告)日：2012-06-14
申请号：US13336523
申请日：2011-12-23
Applicant: Adrian Ion Bot , Chih-Sheng Chiang , David C. Diamond , Jian Gong , Kent Andrew Smith , Liping Liu , Xiping Liu , Zhiyong Qiu
Inventor： Adrian Ion Bot , Chih-Sheng Chiang , David C. Diamond , Jian Gong , Kent Andrew Smith , Liping Liu , Xiping Liu , Zhiyong Qiu
CPC classification number: A61K39/0011 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K39/00 , A61K2039/53 , A61K2039/545 , C07K14/4748 , C07K14/70539 , C12N15/8509
Abstract: The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Abstract translation: 本发明提供了通过向有需要的受试者提供包含质粒和肽或其类似物的免疫原性组合来治疗细胞增殖性疾病如癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效的抗癌免疫应答的方法和组合物。
-
2.发明申请METHODS AND COMPOSITIONS TO ELICIT MULTIVALENT IMMUNE RESPONSES AGAINST DOMINANT AND SUBDOMINANT EPITOPES, EXPRESSED ON CANCER CELLS AND TUMOR STROMA 失效针对癌细胞和肿瘤细胞表达的主要和亚细胞抗原决定多种免疫应答的方法和组合公开(公告)号：US20110269949A1
公开(公告)日：2011-11-03
申请号：US13179042
申请日：2011-07-08
Applicant: Zhiyong Qiu , Adrian Ion Bot
Inventor： Zhiyong Qiu , Adrian Ion Bot
IPC: C07H21/04
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/545 , A61K2039/70 , C07K14/4748 , C07K14/705
Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Abstract translation: 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效的抗癌免疫应答的方法和组合物。
-
公开(公告)号：US20090131355A1
公开(公告)日：2009-05-21
申请号：US12126855
申请日：2008-05-23
Applicant: Adrian Ion Bot , David C. Diamond , Zhiyong Qiu
Inventor： Adrian Ion Bot , David C. Diamond , Zhiyong Qiu
IPC: A61K31/7088 , C12N15/63 , C12N5/10
CPC classification number: C12N15/111 , A61K39/00 , C12N15/1135 , C12N15/85 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2330/30 , C12N2840/20
Abstract: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.
Abstract translation: 本发明的实施方案涉及多顺反子载体及其设计方法。 本发明的方法和组合物包括包含至少两个顺反子的载体，其中第一顺反子包含第一启动子和编码一种或多种治疗剂的第一核酸序列，并且其中第二顺反子包含第二启动子和第二核酸 编码干扰生物反应调节剂或治疗剂表达的一种或多种RNA分子的序列，其中第一序列的表达受第一启动子的控制，第二序列的表达受第二启动子的控制。
-
公开(公告)号：US20080124352A1
公开(公告)日：2008-05-29
申请号：US11323520
申请日：2005-12-29
Applicant: David C. Diamond , Adrian Ion Bot
Inventor： David C. Diamond , Adrian Ion Bot
CPC classification number: A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/292 , A61K39/39 , A61K2039/54 , A61K2039/545 , A61K2039/55561 , A61K2039/57 , C12N2730/10134 , C12N2740/16234
Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
Abstract translation: 本文公开的本发明的实施方案涉及用于在产生抗体和MHC I类限制性免疫应答时绕过CD4 +细胞的参与的方法和组合物，控制反应的性质和量值，以及促进对病毒发病机理的有效免疫干预。 更具体地，实施方案涉及针对HIV和其它影响免疫系统功能的其它微生物病原体的疫苗接种的免疫原性组合物，其性质以及它们有效使用的给药顺序，时间和途径。
-
5.发明授权Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma 失效在癌细胞和肿瘤基质上表达的显性和亚显性表位引发多价免疫应答的方法和组合物公开(公告)号：US08674081B2
公开(公告)日：2014-03-18
申请号：US13179042
申请日：2011-07-08
Applicant: Zhiyong Qiu , Adrian Ion Bot
Inventor： Zhiyong Qiu , Adrian Ion Bot
IPC: C07H21/02
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/545 , A61K2039/70 , C07K14/4748 , C07K14/705
Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Abstract translation: 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效抗癌免疫应答的方法和组合物。
-
Patent Agency Ranking
6.发明申请COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF CANCERS 审中-公开肿瘤相关抗原组合物在各种类型的癌症中的组合公开(公告)号：US20090148478A1
公开(公告)日：2009-06-11
申请号：US12253213
申请日：2008-10-16
Applicant: Chih-Sheng CHIANG , Adrian Ion BOT , John J.L. SIMARD , David C. DIAMOND
Inventor： Chih-Sheng CHIANG , Adrian Ion BOT , John J.L. SIMARD , David C. DIAMOND
IPC: A61K39/00 , A61K31/7088
CPC classification number: A61K39/0011 , A61K48/00 , A61K2039/53 , A61K2039/545
Abstract: Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types of cancer. Both immunogenic compositions for inducing an immune response to these combinations of antigens and methods for their use are disclosed.
Abstract translation: 本文公开了用于诱导针对肿瘤相关抗原的各种组合的免疫应答的方法和组合物，其可以促进对病原性过程的有效的免疫介入。 本文公开的本发明的实施方案涉及使用TuAAs的有效组合用于患有各种类型的癌症的患者的免疫治疗。 公开了用于诱导针对这些抗原组合的免疫应答的免疫原性组合物及其使用方法。
-
公开(公告)号：US08703142B2
公开(公告)日：2014-04-22
申请号：US11323520
申请日：2005-12-29
Applicant: David C. Diamond , Adrian Ion Bot
Inventor： David C. Diamond , Adrian Ion Bot
CPC classification number: A61K39/0011 , A61K39/12 , A61K39/21 , A61K39/292 , A61K39/39 , A61K2039/54 , A61K2039/545 , A61K2039/55561 , A61K2039/57 , C12N2730/10134 , C12N2740/16234
Abstract: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions for vaccination particularly therapeutic vaccination, against HIV and other microbial pathogens that impact functioning of the immune system, their nature, and the order, timing, and route of administration by which they are effectively used.
Abstract translation: 本文公开的本发明的实施方案涉及用于在产生抗体和MHC I类限制性免疫应答时绕过CD4 +细胞的参与的方法和组合物，控制反应的性质和量值，以及促进对病毒发病机理的有效免疫干预。 更具体地，实施方案涉及针对HIV和其它影响免疫系统功能的其它微生物病原体的疫苗接种的免疫原性组合物，其性质以及它们有效使用的给药顺序，时间和途径。
-
公开(公告)号：US08653237B2
公开(公告)日：2014-02-18
申请号：US13481741
申请日：2012-05-25
Applicant: Liping Liu , Adrian Ion Bot , David C. Diamond
Inventor： Liping Liu , Adrian Ion Bot , David C. Diamond
IPC: A61K38/06 , A61K38/00 , A61K51/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00
CPC classification number: C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0008 , A61K48/00 , A61K2035/122 , A61K2039/53 , A61K2039/57 , A61K2039/645 , C07K7/06 , C07K14/47 , C07K14/70503
Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Abstract translation: 一些实施方案涉及对应于I类MHC限制性T细胞表位的肽类似物及其产生方法。 这些类似物可以在与MHC分子直接相互作用的残基处含有氨基酸取代，并且可以赋予改进的，修饰的或有用的免疫学特性。 此外，公开了类似物类别，其中各种取代包括非标准残基正亮氨酸和/或正缬氨酸。
-
公开(公告)号：US20110230548A1
公开(公告)日：2011-09-22
申请号：US13032635
申请日：2011-02-22
Applicant: Adrian Ion Bot , David C. Diamond , Zhiyong Qiu
Inventor： Adrian Ion Bot , David C. Diamond , Zhiyong Qiu
CPC classification number: C12N15/111 , A61K39/00 , C12N15/1135 , C12N15/85 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2330/30 , C12N2840/20
Abstract: Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.
Abstract translation: 本发明的实施方案涉及多顺反子载体及其设计方法。 本发明的方法和组合物包括包含至少两个顺反子的载体，其中第一顺反子包含第一启动子和编码一种或多种治疗剂的第一核酸序列，并且其中第二顺反子包含第二启动子和第二核酸 编码干扰生物反应调节剂或治疗剂表达的一种或多种RNA分子的序列，其中第一序列的表达在第一启动子的控制下，第二序列的表达受第二启动子的控制。
-
10.发明授权Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma 有权在癌细胞和肿瘤基质上表达的显性和亚显性表位引发多价免疫应答的方法和组合物公开(公告)号：US07999088B2
公开(公告)日：2011-08-16
申请号：US11454616
申请日：2006-06-16
Applicant: Zhiyong Qiu , Adrian Ion Bot
Inventor： Zhiyong Qiu , Adrian Ion Bot
CPC classification number: A61K39/0011 , A61K2039/53 , A61K2039/545 , A61K2039/70 , C07K14/4748 , C07K14/705
Abstract: The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Abstract translation: 本发明提供了一种通过向有需要的受试者提供包含编码包含CTL表位PSMA288-297和PRAME425-433或交叉反应性类似物的多肽的核酸构建体的免疫原性组合来治疗癌症的方法。 在本发明的实施方案中，提供了用于诱导，携带和/或扩增针对癌抗原的MHC I类限制性表位的免疫应答以产生有效的抗癌免疫应答的方法和组合物。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.021 seconds)
